FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
KOSKI FAMILY LP
  2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [OGEN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
3525 TURTLE CREEK BOULEVARD, UNIT 19-B
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2014
(Street)

DALLAS, TX 75219
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2014   J V 906,000 (1) D $ 0 8,257,742 D (2) (3)  
Common Stock 01/21/2014   J V 300,000 (1) A $ 0 1,065,729 D (4)  
Common Stock 01/21/2014   J V 300,000 (1) A $ 0 592,878 D (5)  
Common Stock 01/21/2014   J V 300,000 (1) A $ 0 969,666 D (6)  
Common Stock 01/21/2014   J V 6,000 (1) A $ 0 20,000 I (7) By Koski Management, Inc.
Common Stock               530,851 I (8) By Trusts

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
KOSKI FAMILY LP
3525 TURTLE CREEK BOULEVARD, UNIT 19-B
DALLAS, TX 75219
    X    
KOSKI ROBERT C
7362 HAWKINS ROAD
SARASOTA, FL 34241
  X   X    
KOSKI THOMAS L
4995 ASHLEY PARKWAY
SARASOTA, FL 34241
    X    
KOSKI BEVERLY
3525 TURTLE CREEK BOULDEVARD, UNIT 19-B
DALLAS, TX 75219
    X    
KOSKI CHRISTINE L
3525 TURTLE CREEK BOULEVARD, UNIT 19-B
DALLAS, TX 75219
  X   X    

Signatures

 /s/ Mark A. Catchur, as Attorney-in-Fact for CHRISTINE L. KOSKI, BEVERLY KOSKI, KOSKI FAMILY LIMITED PARTNERSHIP, ROBERT C. KOSKI AND THOMAS L. KOSKI   02/03/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On January 21, 2014, the Koski Family Limited Partnership ("KFLP") authorized a distribution of 906,000 shares of Oragenics, Inc. common stock to the KFLP's underlying partners: Beverly Koski (through Koski Management, Inc.); Christine L. Koski; Robert C. Koski; and Thomas L. Koski on a pro rata basis, in accordance with their ownership interests in the KFLP.
(2) Shares owned directly by Koski Family Limited Partnership. Shares owned indirectly by Beverly Koski (through Koski Management, Inc. solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership.
(3) Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.
(4) Shares owned directly by Christine L. Koski.
(5) Shares owned directly by Robert C. Koski.
(6) Shares owned directly by Thomas L. Koski.
(7) Shares owned indirectly by Beverly Koski (through Koski Management, Inc).
(8) Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (107,600 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (107,600 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (107,600 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (108,051 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.